Effect of Laser Acupoints on Fallopian Tube Obstruction

January 10, 2026 updated by: Hadeer Elsaid Abd-Elsalam Shalaby, Kafrelsheikh University
This study aims to determine the efficacy of laser acupoint therapy on treating fallopian tube obstruction.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Fallopian tube obstruction is a significant health concern that affects a substantial number of women worldwide, often leading to infertility and other reproductive issues. The fallopian tubes, essential components of the female reproductive system, play a crucial role in the process of conception by facilitating the transport of ova from the ovaries to the uterus.

The laser's focused light energy, when directed at specific acupoints linked to reproductive health, is hypothesized to activate the body's energy pathways or meridians, thereby facilitating healing and restoration of normal tubal function.

Although acupoint therapy shows promise, laser acupoint therapy offers potential advantages over traditional acupuncture by utilizing low-level lasers, which may enhance the treatment's efficacy. Laser acupoint therapy is noninvasive and painless, making it articularly appealing for patients who have a fear of needles or are sensitive to pain.

Study Type

Interventional

Enrollment (Estimated)

36

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Egypt
    • Kafrelsheikh
      • Kafr ash Shaykh, Kafrelsheikh, Egypt, 33516
        • Recruiting
        • Kafrelsheikh University (Faculty of Physical Therapy)
        • Sub-Investigator:
          • Fayiz F Elshamy, MD
        • Contact:
        • Sub-Investigator:
          • Mostafa F Ellkany, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Women aged 20-35 years - nulliparous.
  • Women diagnosed with fallopian tube obstruction.
  • Body mass index less than 30 kg/m2.
  • Consent to participate in the study.
  • General good health with no major co-existing medical conditions that could interfere with the treatment or outcomes.
  • No prior fertility treatments [e.g., In vitro fertilization (IVF), intrauterine insemination (IUI)] within the last 6 months.
  • Ability to attend all scheduled sessions and follow-up assessments.

Exclusion Criteria:

  • Currently pregnant or breastfeeding.
  • History of pelvic surgery within the past year.
  • Presence of severe systemic diseases such as active cancer or severe cardiovascular diseases.
  • History of allergic reactions or adverse responses to acupuncture or laser therapies.
  • Currently undergoing hormonal therapy or use of hormonal contraceptives.
  • Current or recent history of genital tract infections, including sexually transmitted. infections, which could affect the reproductive system.
  • Presence of significant uterine anomalies diagnosed through imaging that could impact fertility.
  • Polycystic Ovary Syndrome (PCOS).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Study Group (Group A)
Patients will receive laser acupoints therapy addition to standard care.
Other: Laser acupoints therapy + Standard care
Patients will receive laser acupoints therapy addition to standard care.
Placebo Comparator: Control Group (Group B)
Patients will receive placebo laser acupoints therapy in addition to standard care.
Other: Standard care
Patients will receive placebo laser acupoints therapy in addition to standard care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Tubal patency
Time Frame: 3 months post-treatment
Hysterosalpingography (HSG) will be used to assess tubal patency. It is a radiographic technique where a contrast material is injected into the uterine cavity, and X-ray images are taken to evaluate the shape of the uterus and the status of the fallopian tubes. HSG will be applied before the treatment and again three months post-treatment to evaluate changes in tubal patency HSG will be applied before treatment and after 3 months post-treatment.
3 months post-treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anti-Müllerian Hormone (AMH) Test
Time Frame: 3 months post-treatment
A blood test will be used to measure the level of Anti-Müllerian Hormone (AMH), which is an indicator of the remaining quantity of eggs and ovarian function. This test will be conducted before the treatment and at the third month of treatment to monitor any changes in ovarian reserve.
3 months post-treatment
Quantitative Pregnancy Test
Time Frame: 3 months post-treatment
A blood test that will be measured the specific level of Human Chorionic Gonadotropin (hCG), which is produced during pregnancy. This test will be performed every month.
3 months post-treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Kafrelsheikh University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2025

Primary Completion (Estimated)

April 1, 2026

Study Completion (Estimated)

April 1, 2026

Study Registration Dates

First Submitted

January 10, 2026

First Submitted That Met QC Criteria

January 10, 2026

First Posted (Actual)

January 20, 2026

Study Record Updates

Last Update Posted (Actual)

January 20, 2026

Last Update Submitted That Met QC Criteria

January 10, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • KFSIRB200-711

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

IPD Sharing Time Frame

After the end of study for one year.

IPD Sharing Access Criteria

The data will be available upon a reasonable request from the corresponding author.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Laser

Clinical Trials on Laser acupoints therapy + Standard care

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe